MedTrace Logo

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes

NCT00659282 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57610

Last updated 2018-01-12

No results posted yet for this study

Summary

This study is conducted in Asia, Europe, Japan and North America. The aim of this observational study is to evaluate the safety and effectiveness while using NovoMix® 30 during 26 weeks under normal clinical practice, in the countries participating in the study. The primary outcome is the incidence of major hypoglycaemic events reported as serious adverse drugs reaction conditions on hypoglycaemic events.

Conditions

Interventions

DRUG

biphasic insulin aspart

Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-11
Primary Completion
2008-11-15
Completion
2008-11-15

Countries

  • Canada
  • China
  • Greece
  • India
  • Iran
  • Italy
  • Japan
  • Poland
  • Russia
  • Saudi Arabia
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659282 on ClinicalTrials.gov